In brief: Dreem connects to Amazon, CMS highlights digital health, AdaptHealth refinances

NEW YORK – Dreem Health, a virtual sleep clinic managed by Sunrise Group, says it has become the first sleep care service to join Amazon’s Health Benefits Connector.

Amazon customers eligible for insurance-covered sleep services can now discover and enroll in Dreem Health’s personalized care when browsing for health care services.

“Millions of people live with undiagnosed sleep disorders that quietly impact their health, productivity, and quality of life,” said Laurent Martinot, co-founder and CEO of Sunrise Group. “By joining Amazon’s Health Benefits Connector, we’re helping surface sleep care as a covered benefit and making it far easier for people to take the first step toward better sleep.”

Dreem Health says its FDA-cleared home sleep test provides hospital-quality diagnostics without requiring clinic visits, while ongoing patient support ensures treatment adherence, improving outcomes and reducing preventable complications.

By joining forces, Amazon and Dreem Health say they are connecting the dots for consumers, making it easier than ever for individuals to move from discovering their benefits to receiving high-quality care.

"As a customer-centered organization, our Health Benefits Connector is designed to help customers find and use trusted health services that may already be provided by their insurer or employer,” said John Singerling, head of strategic growth and network development for Amazon Health Services. “By connecting customers with services like Dreem Health through Health Benefits Connector, we’re helping make it easier to discover care that supports better health outcomes."

The announcement comes on the heels of a $29 million raise by Sunrise Group to support the expansion of the company's clinical services and accelerate its investment in next-generation sleep technology.

• Related: Sunrise Group acquires Dreem Health.
• Related: Dreem Health has launched a women’s health program for women experiencing sleep issues due to pregnancy.

Researchers develop algorithm to predict impact of CPAP therapy on cardiovascular disease

NEW YORK – Researchers at Mount Sinai have created an analytic tool using machine learning that they say can predict cardiovascular disease risk in millions of patients with obstructive sleep apnea, according to findings recently published in Communications Medicine.

The researchers used a machine learning algorithm to create an analysis model that they say predicts how CPAP could affect an individual’s cardiovascular health – estimating each patient’s likeliness of benefit or harm from the therapy, based on their sleep and health information.

“Our findings represent a significant advancement in personalized medicine, moving away from a one-size-fits-all strategy in the treatment of obstructive sleep apnea,” said co-corresponding author Neomi A. Shah, MD, MPH, MSC, professor of medicine (pulmonary, critical care and sleep medicine), and artificial intelligence and human health, and associate chief for academic affairs in the Division of Pulmonary, Critical Care and Sleep Medicine at the Icahn School of Medicine at Mount Sinai. “This underscores the value of new data-driven approaches like our model to assist clinicians in making informed decisions about CPAP treatment recommendations, enhancing personalized care to meet the individual needs of every patient.”

Researchers analyzed data from the Sleep Apnea Cardiovascular Endpoints (SAVE) trial, the largest clinical cohort evaluating CPAP for cardiovascular disease prevention with more than 2,600 participants from 89 sites in seven countries, to estimate individualized treatment effect scores. They considered more than 100 predictors from sleep and health information to establish 23 key baseline features, such as prior medical conditions and smoking status, in their analysis model.

Researchers found that treatment response significantly varied across the cohort. The model identified a subgroup who were expected to have improved cardiovascular risk with CPAP treatment; participants in this subgroup who were randomly assigned to receive the therapy experienced a 100-fold improvement in future cardiac risk compared with usual care. Conversely, those in a subgroup predicted to be harmed by the therapy experienced a greater than 100-fold increase in cardiovascular disease outcomes, including recurrent strokes and heart attacks, when receiving CPAP compared with usual care.

“These results demonstrate the power of machine learning for prediction of treatment effects in an era of precision medicine; however, such models require careful validation to prove their utility in clinical practice,” said co-primary author Oren Cohen, MD, assistant professor of medicine (pulmonary, critical care and sleep medicine) at the Icahn School of Medicine.

• Related: PAP adherence reduces cardiovascular related health events (CVRHU) in patients with obstructive sleep apnea, according to a new study published in Sleep and supported by Resmed.

CMS highlights new digital health tools

WASHINGTON – The Centers for Medicare & Medicaid Services (CMS) has released a new Medicare App Library and an initial set of patient-facing applications as part of its HealthTech Ecosystem Live! First Wave Launch event. The agency introduced interoperable tools to streamline care and improve patient experience, including:

• Digital data access and check‑in (“Kill the Clipboard”), allowing patients to securely share information with a simple scan on their phone.
• Personalized health applications, offering tailored guidance on nutrition, wellness, and chronic disease management – extending care beyond clinic walls.

CMS highlighted tools from more than 50 companies – many of which are already accessible or will be available to the public soon. The agency previously called on industry last year to help build a modern digital health ecosystem, with more than 700 organizations pledging support. The agency says the First Wave Launch marks a significant step toward a fully digital, patient-centered health system.

AdaptHealth refinances senior secured credit facility

CONSHOHOCKEN, Pa. – AdaptHealth has closed a $1.1 billion senior secured credit facility consisting of a $325 million Term Loan A, a $325 million Delayed Draw Term Loan and a $450 million revolving line of credit. The company believes these upgrades, along with consistent free cash flow generation, directly contributed to the improved terms achieved in the new credit facility, including a meaningfully reduced pricing grid that reflects lender recognition of its stronger credit standing. “The terms of this new credit facility are a direct reflection of the significant progress we have made transforming AdaptHealth’s financial and operational profile over the past several years,” said CFO Jason Clemens. “The recent upgrades from both S&P and Moody’s, combined with the strong support from our banking partners – including a well-oversubscribed syndication process – validate the work our team has done to build a more resilient and higher-performing company. The improved pricing, expanded capacity, and extended maturity provide us with the financial foundation to continue delivering value to our patients, partners, and shareholders.” According to AdaptHealth:

• Proceeds from the new $325 million Term Loan were used to fully repay, without penalty, the company’s existing Term Loan.
• The new $450 million revolver replaces the company’s existing $300 million revolving credit facility, which had $100 million drawn at the time the credit facility closed.
• The increased revolver size provides enhanced liquidity to support the company’s ongoing operations.
• The $325 million Delayed Draw Facility provides the company with committed capital that may be drawn in up to two advances over a one-year availability period.

AdaptHealth does not expect the transaction to affect the full year 2026 guidance previously provided.

• Related: AdaptHealth’s fast start on contract boost confidence.

FDA seeks med tech innovation to strengthen home care

WASHINGTON – The U.S. Food and Drug Administration (FDA) has launched the Reducing Readmissions through Device Innovation for the Home (READI-Home) Innovation Challenge to accelerate patient access to medical device technologies aimed at reducing hospital readmission. As part of the FDA’s Center for Devices and Radiological Health’s (CDRH) Home as a Health Care Hub Initiative, the FDA invites innovators to pursue potential participation in the challenge by submitting proposed solutions for medical device technologies to be used in the home setting. These technologies would support patients and caregivers after an acute hospital stay and may help prevent avoidable readmissions. The challenge includes multiple phases:

• A submission period from April 7 – Sept. 30
• A selection period from Oct. 1 – Dec. 4
• An interaction period begins Dec. 5

The FDA anticipates selecting up to 9 devices from distinct manufacturers to move on to the interaction phase. It will consider:

• Description of the device and the clinical challenge it is intended to address
• Novelty of the device/concept
• Current development status of the device
• Data development plan (DDP) for the device
• Overview of key expertise within the team
• Anticipated impact

For more information, including how to submit a device, go here.

Aeroflow Health supports efforts to extend Medicaid coverage in Wisconsin

ASHEVILLE, N.C. – Aeroflow Health supports the passage of the 2025 Wisconsin Act 102 to expand postpartum Medicaid coverage from 60 days to one year. The company says the act, which goes into effect July 1, 2026, means mothers in the state now have more time to focus on recovery and explore the care resources available for themselves and their babies. “Extended Medicaid coverage during the first year of postpartum gives mothers peace of mind that care will be there when they need it,” said Ryan Bullock, chief strategy officer at Aeroflow Health. “With new moms no longer needing to worry about their coverage ending after two months, they can instead focus on what truly matters – recovery, nurturing their baby and building strong foundations for their families. Aeroflow applauds this effort and is proud to have been a part of advocating for this change.” Aeroflow played a key role in advocating for Senate Bill 23, the legislation leading to the act. The company has also successfully advocated for the passage of expanded breast pump coverage in Wisconsin, as well as for tax exemptions on medically necessary products in Maine, Nevada, Texas, Florida, Ohio and North Carolina.

• Related: Aeroflow Health has a new partnership with Johns Hopkins Health Plans and the Maryland Community Health System to provide Priority Partners, a Medicaid managed care organization (MCO), with durable medical equipment (DME) for its members across Maryland.

WHILL: Let’s rethink how we view mobility devices

ORLANDO, Fla. – WHILL has released a white paper, “Designing for Dignity: Reshaping Perceptions of Mobility,” to explore how design, technology and human-centered thinking are redefining how people adopt and experience mobility solutions. The company, which offers autonomous mobility services, says the report highlights a critical insight: While mobility devices are traditionally viewed through a clinical lens, emotional and social barriers, rather than physical limitations, are often the primary drivers delaying adoption. "Mobility is not just about movement, it's about identity, confidence, and how people move through the world," said Satoshi Sugie, CEO of WHILL. "When design prioritizes dignity, mobility becomes something people embrace, not something they resist." WHILL conducted research and found 96% of users feel safer, more confident, or more independent after adopting a design-forward mobility device, and 90% report greater independence. Key insights from the white paper include:

• Stigma remains a primary barrier to mobility adoption.
• Mobility device design is evolving to better reflect both functional needs and personal identity.
• Design-forward mobility reframes devices as tools of agency, autonomy, and identity.
• Consumer-centric design improves independence, inclusion, and daily usage.
• Aging populations are accelerating demand for modern, design-led solutions.

The white paper also explores the psychological barriers behind delayed adoption, including fear of permanence, internalized bias and lack of representation.

• Related: WHILL powers up.

Soleo Health enters Louisville market

FRISCO, Texas – Soleo Health has opened a new ambulatory infusion center (AIC) in Louisville, Ky. “Our Louisville AIC expansion will allow us to reach more patients who benefit from complex specialty therapies and enhance services offered to providers,” said Craig Vollmer, chief commercial officer for Soleo Health. “Our goal is to work alongside local physicians and care teams to help ensure patients have timely access to therapies in a setting that prioritizes comfort, safety, and personalized care.” Soleo Health Louisville is staffed by experienced nurses, supported by the company’s therapeutic care management pharmacists and staff, dedicated to supporting patients with complex, rare or ultra-rare conditions, including chronic inflammatory demyelinating polyneuropathy (CIDP), dermatomyositis, myasthenia gravis (MG), primary immunodeficiencies (PI) and thyroid eye disease (TED) as well as multiple sclerosis (MS), Crohn’s disease, rheumatoid arthritis (RA) and ulcerative colitis (UC), among others. The company also recently opened a new AIC in Austin, Texas.

ProSomnus: ‘We are enabling smart sleep medicine’

SAN FRANCISCO – ProSomnus Sleep Technologies has announced that the U.S. Food and Drug Administration (FDA) has granted Class II 510(k) clearance for its RPMO₂ OSA Device under the product codes DQA, LQZ, LRK, PLC, and OUG (FDA K252765). The company says the RPMO2 OSA Device is the first theranostic device for sleep medicine, incorporating both precision oral appliance therapy and multi-night physiologic monitoring in one device. With this new clearance, it says the device is positioned as a cornerstone of a new smart sleep medicine era characterized by connected, patient centric, evidence-driven OSA care. “The FDA’s clearance of the RPMO₂ OSA Device marks a significant milestone for sleep medicine,” stated Len Liptak, CEO of ProSomnus. “By integrating safe, accurate, continuous physiologic measurement into our precision oral appliance platform, we are enabling smart sleep medicine – a connected, data driven model that helps clinicians manage sleep apnea as the personal, individualized and chronic disease it truly is.” Earlier this year, ProSomnus raised $38 million through a strategic investment from Catalio Capital Management to accelerate the expansion of its sleep health platform.